A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

Withdrawn before enrolling · Phase 1 · Has a placebo group

Conditions studied: Ulcerative Colitis

In brief

To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule) versus placebo in subjects with active mild to moderate ulcerative colitis (UC).

Key facts

Study ID

NCT06260267

Run by

Ferring Pharmaceuticals

People needed

0

Starts

2024-03-12

Expected to finish

2026-01-15

Last updated by the study team

2024-10-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject aged ≥18 at screening
• Established diagnosis of ulcerative colitis by standard clinical, endoscopic and histological criteria, for more than 3 months at screening

You may not qualify if…

• Active disease or history of Crohn's disease
• Active disease or history of irritable bowel syndrome (IBS) or any other chronic intestinal disease apart from UC
• Active gastrointestinal infection.

Where it is running

• Ferring Investigational Site — North Little Rock, Arkansas, United States
• Ferring Investigational Site — Hamden, Connecticut, United States
• Ferring Investigational Site — Inverness, Florida, United States
• Ferring Investigational Site — Jacksonville, Florida, United States
• Ferring Investigational Site — Orange City, Florida, United States
• Ferring Investigational Site — Glenview, Illinois, United States
• Ferring Investigational Site — Gurnee, Illinois, United States
• Ferring Investigational Site — Shreveport, Louisiana, United States
• Ferring Investigational Site — Boston, Massachusetts, United States
• Ferring Investigational Site — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.